Guest guest Posted November 19, 2004 Report Share Posted November 19, 2004 Senate Finance Committee -- Vioxx Health Risks Full committee hearing on " FDA, Merck, and Vioxx: Putting Patient Safety First? " Witnesses: Lester Crawford, acting commissioner, Food and Drug Administration (FDA) Graham, associate director for science, Office of Drug Safety, Center for Drug Evaluation and Research, FDA; Gurkirpal Singh, adjunct clinical professor of medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine; Bruce Psaty, professor of medicine and epidemiology, University of Washington, Cardiovascular Health Research Unit; Gilmartin, chairman/president/CEO, Merck & Co. Inc., Whitehouse Station, N.J. Location: 215 Dirksen Senate Office Building. 10 a.m. Contact: 202-224-4515 http://finance.senate.gov/ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 19, 2004 Report Share Posted November 19, 2004 Senate Finance Committee -- Vioxx Health Risks Full committee hearing on " FDA, Merck, and Vioxx: Putting Patient Safety First? " Witnesses: Lester Crawford, acting commissioner, Food and Drug Administration (FDA) Graham, associate director for science, Office of Drug Safety, Center for Drug Evaluation and Research, FDA; Gurkirpal Singh, adjunct clinical professor of medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine; Bruce Psaty, professor of medicine and epidemiology, University of Washington, Cardiovascular Health Research Unit; Gilmartin, chairman/president/CEO, Merck & Co. Inc., Whitehouse Station, N.J. Location: 215 Dirksen Senate Office Building. 10 a.m. Contact: 202-224-4515 http://finance.senate.gov/ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 19, 2004 Report Share Posted November 19, 2004 Senate Finance Committee -- Vioxx Health Risks Full committee hearing on " FDA, Merck, and Vioxx: Putting Patient Safety First? " Witnesses: Lester Crawford, acting commissioner, Food and Drug Administration (FDA) Graham, associate director for science, Office of Drug Safety, Center for Drug Evaluation and Research, FDA; Gurkirpal Singh, adjunct clinical professor of medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine; Bruce Psaty, professor of medicine and epidemiology, University of Washington, Cardiovascular Health Research Unit; Gilmartin, chairman/president/CEO, Merck & Co. Inc., Whitehouse Station, N.J. Location: 215 Dirksen Senate Office Building. 10 a.m. Contact: 202-224-4515 http://finance.senate.gov/ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 19, 2004 Report Share Posted November 19, 2004 Senate Finance Committee -- Vioxx Health Risks Full committee hearing on " FDA, Merck, and Vioxx: Putting Patient Safety First? " Witnesses: Lester Crawford, acting commissioner, Food and Drug Administration (FDA) Graham, associate director for science, Office of Drug Safety, Center for Drug Evaluation and Research, FDA; Gurkirpal Singh, adjunct clinical professor of medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine; Bruce Psaty, professor of medicine and epidemiology, University of Washington, Cardiovascular Health Research Unit; Gilmartin, chairman/president/CEO, Merck & Co. Inc., Whitehouse Station, N.J. Location: 215 Dirksen Senate Office Building. 10 a.m. Contact: 202-224-4515 http://finance.senate.gov/ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.